Better Remissions, Fewer Side Effects: Nivolumab + AVD in HL | Alex Herrera MD

MPN & Splanchnic Vein Thrombosis: Key Takeaways for Patients | Douglas Tremblay, MD

Can Nadir Bone Marrow Predict AML Outcomes? New Trial Data | Douglas Tremblay, MD

Can Nadir Bone Marrow Predict AML Outcomes? New Trial Data | Douglas Tremblay, MD

What Happens When You Add Mosunetuzumab + Polatuzumab to CAR‑T (axi‑cel)? | Jay Spiegel, MD

What Happens When You Add Mosunetuzumab + Polatuzumab to CAR‑T (axi‑cel)? | Jay Spiegel, MD

New SEQUOIA Trial Results Shake Up First‑Line CLL Care! | Amit Agarwal, MD, PhD

New SEQUOIA Trial Results Shake Up First‑Line CLL Care! | Amit Agarwal, MD, PhD

Non-Covalent vs Covalent BTK Inhibitors: What’s Best of Patients | Jennifer Woyach, MD

Non-Covalent vs Covalent BTK Inhibitors: What’s Best of Patients | Jennifer Woyach, MD

SMART STOP Trial: Targeted Drugs Before Chemo in B-Cell Lymphoma? | Jason Westin, MD

SMART STOP Trial: Targeted Drugs Before Chemo in B-Cell Lymphoma? | Jason Westin, MD

Is the Blexi‑Ven Combo Safe and Effective? | Jenny O'Nions, MD

Is the Blexi‑Ven Combo Safe and Effective? | Jenny O'Nions, MD

Is Time-Limited Therapy the Future for CLL? | Romain Guieze, MD

Is Time-Limited Therapy the Future for CLL? | Romain Guieze, MD

Checkpoint Inhibitors Show High Response in Hard-to-Treat Lymphoma | Vincent Camus, MD, PhD

Sonrotoclax Could Be a Game‑Changer for MCL? | Amit Agarwal, MD, PhD

Is Rocbrutinib a New Option for CLL Patients? Phase 1 Trial Updates | Jennifer Woyach, MD